- 4-Hydroxyisoleucine
-
- $30.00 / 5mg
-
2026-04-22
- CAS:781658-23-9
- Min. Order:
- Purity: 99.83%
- Supply Ability: 10g
- 4-Hydroxy-L-isoleucine
-
- $0.00 / 1kg
-
2025-04-04
- CAS:781658-23-9
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- 4-Hydroxy-L-isoleucine
-
- $1090.00 / 50g
-
2024-04-02
- CAS:781658-23-9
- Min. Order: 1g
- Purity: 98
- Supply Ability: 500 Kg
|
| | 4-Hydroxy-L-isoleucine Basic information |
| | 4-Hydroxy-L-isoleucine Chemical Properties |
| Melting point | >200° | | Boiling point | 332 ºC | | density | 1.181 | | Fp | 147 ºC | | storage temp. | 2-8°C | | pka | 2.41±0.25(Predicted) | | form | powder | | color | White | | Optical Rotation | [α]/D +34.0±2.0°, c = 1 in H2O | | Water Solubility | Soluble in water | | InChI | 1S/C6H13NO3/c1-3(4(2)8)5(7)6(9)10/h3-5,8H,7H2,1-2H3,(H,9,10)/t3-,4,5-/m0/s1 | | InChIKey | OSCCDBFHNMXNME-UHFFFAOYSA-N | | SMILES | CC(O)[C@H](C)[C@H](N)C(O)=O | | CAS DataBase Reference | 781658-23-9(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | HS Code | 2922505000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | 4-Hydroxy-L-isoleucine Usage And Synthesis |
| Chemical Properties | 4-Hydroxyisoleucine is Light Yellow Solid | | Uses | 4-Hydroxy-L-isoleucine is used as a treatment for type II diabetes. | | Definition | ChEBI: 4-Hydroxy-L-isoleucine is an isoleucine derivative. | | Biochem/physiol Actions | A peculiar amino acid extracted from fenugreek seeds and never found in mammalian tissues, exhibits interesting insulinotropic activity; effects on insulin secretion, plant-derived treatment for metabolic syndrome. | | in vivo | 4-Hydroxyisoleucine (50 mg/kg, p.o., daily, 8 weeks) inhibits the increase in serum glucose in the fructose-fed rat model of metabolic syndrome[1].
4-Hydroxyisoleucine (200 mg/kg, p.o., 8 weeks) improves dyslipidemia and reduces lipid ectopic accumulation in C57BL/6 mice[4].
4-Hydroxyisoleucine (200 mg/kg, p.o., 8 weeks) decreases the expression of proinflammatory cytokine (IL-6, PAI-1, IL-1β, NF-κB, TNF-α, and MCP-1) and the proportion of proinflammatory M1 macrophages in C57BL/6 mice[4].
4-Hydroxyisoleucine (50 mg/kg, i.g., daily, 14 days) restores high levels of lipids (cholesterol, HDL, LDL and triglycerides) and uric acid in type 1 diabetic rat to that of nondiabetic controls level[5]. | Animal Model: | Fructose-fed rat[1] | | Dosage: | 50 mg/kg | | Administration: | Oral gavage (p.o.), daily, 8 weeks | | Result: | Decreased the levels of glucose and ALT.
Reduced 80% of fructosehe-induced AST release to 151 ± 45 U/mL.
|
| Animal Model: | Type 2 diabetic rat[1] | | Dosage: | 50 mg/kg | | Administration: | i.g., daily, 14 days | | Result: | Restored the level of HDL-cholesterol to levels comparable to controls.
|
| Animal Model: | Male C57BL/6 mice[4] | | Dosage: | 50-200 mg/kg | | Administration: | Oral gavage (p.o.), 8 weeks | | Result: | Decreases the body weights of mice in a dose-dependent manner.
Decreased blood glucose levels and fasting plasma insulin content in mice.
Decreased the expression of TLR4, inhibited the phosphorylation of JNK, and increased the production of IκB-α.
|
| Animal Model: | Type 1 diabetic rat[5] | | Dosage: | 50 mg/kg | | Administration: | i.g., daily, 14 days | | Result: | Improved appearance and heavy ocular vascularization.
Reduced the blood glucose from 500 mg/dl to 330 mg/dl.
Decreased the levels of lipid markers (TG, LDL and HDL) and uric acid.
Didn’t increase the level of inculin compared with untreated diabetic controls.
|
|
| | 4-Hydroxy-L-isoleucine Preparation Products And Raw materials |
|